ReShape Lifesciences Inc expected to post a loss of $10.00 a share - Earnings Preview

Vyome Holdings

24/03/2023 11:02

* ReShape Lifesciences Inc  RSLS.OQ   RSLS.O  is expected
to show
a fall in quarterly revenue when it reports  results on March
29. 
    * The San Clemente California-based  company is expected to
report
 a 1.2% decrease in revenue to $3.103 million from $3.14 million
a year ago, according to the mean estimate from 2 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for ReShape
Lifesciences Inc
is for a loss of $10.00 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ReShape
Lifesciences Inc is $38.75​, above​ its last closing price
of $3.14. ​​​

This summary was machine generated March 24 at 11:02 GMT.  All
figures in US dollars  unless otherwise stated